– UK, Oxford – OBN announces today that industry professionals Denise Goode and Sally Waterman have been appointed to its Board of Directors. Professor Chris Hawes will step down to take up a role on the OBN Advisory Group. The OBN commercial and BioTrinity teams have been strengthened with several new staff members.
OBN Chairman David Laskow-Pooley comments, “We are delighted that Denise Goode and Sally Waterman have agreed to join the OBN Board. Year-on-year, the life sciences industry faces new challenges. It is vital we provide our members with the best available intelligence and understanding so they can position themselves precisely for investment and commercial success. Denise and Sally bring that depth of knowledge from different and complementary lifecycle viewpoints.”
“As Chris Hawes leaves the Board, we wish to acknowledge his instrumental role in founding OBN, then the Oxfordshire Bioscience Network, and his steadfast support and valuable contributions over the last decade. Thankfully Chris will remain in the OBN fold as a member of our Advisory Group.”
About Denise Goode
Denise Goode, Executive Business Development Director, currently on garden leave from AstraZeneca’s Business Development team, brings extensive financial, commercial and industry dealmaking experience. A chartered accountant and biologist by training, Denise joined AstraZeneca in 1994. Since then, Denise has worked in a broad portfolio of strategic and finance roles, and brings over a decade of both buy- and sell-side business development transaction expertise.
About Sally Waterman
Sally Waterman has held R&D leadership and operational roles in a wide range of biopharmaceuticals companies, including Protherics, KS Biomedix and Vernalis since 1995, prior to which she had a career in regulatory affairs in big pharma and the service sector. She joined PolyTherics as COO in 2009 and is currently Senior VP Corporate Development. Sally has been involved in several M&A transactions and has considerable experience of integrating businesses.
OBN is the membership organisation supporting and bringing together the UK’s emerging life science companies, corporate partners and investors within and beyond the Golden Triangle biocluster (formed by Oxford, Cambridge andLondon), providing networking, partnering, group purchasing, advocacy and advice. Through BioTrinity ), UK’s largest annual biopartnering and investment conference – this year expected to attract over 1000 delegates from 30 countries – OBN will generate more R&D-company-to-investor interactions than any other membership organisation in Europe.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.